Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 42 of 42 entries
View as:

Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04595565 Org: User:
Start: 10/28/20 End: 03/30/29 Due: 03/30/30

Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT01594177 Org: User:
Start: 05/31/12 End: 03/31/14 Due: 03/31/15

Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA)

Phase: N/A Priority: Normal
NCT ID: NCT01534455 Org: User:
Start: 02/29/12 End: 03/31/15 Due: 03/31/16

Evaluating the Addition of Elacestrant (oral SERD) to Olaparib (PARP-inhibitor) in Patients with Advanced/metastatic HR+/HER2- Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06201234 Org: User:
Start: 12/13/24 End: 12/31/28 Due: 12/31/29

Nab-paclitaxel in Metastatic Breast Cancer Patients Failing Solvent Based Taxane (Tiffany)

Phase: N/A Priority: Normal
NCT ID: NCT01416558 Org: User:
Start: 07/31/11 End: 10/31/12 Due: 10/31/13

A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN)

Phase: N/A Priority: Normal
NCT ID: NCT00196872 Org: User:
Start: 07/31/04 End: 06/30/14 Due: 06/30/15

Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03555877 Org: User:
Start: 03/15/18 End: 07/21/22 Due: 07/21/23

Study of Nab-Paclitaxel in High Risk Early Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01690702 Org: User:
Start: 09/30/12 End: 07/20/20 Due: 07/20/21

A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).

Phase: N/A Priority: Normal
NCT ID: NCT03355157 Org: User:
Start: 03/01/18 End: 08/30/24 Due: 08/30/25

Prevention of Chemotherapy Induced Ovarian Failure With Goserelin in BC Patients (ZORO)

Phase: N/A Priority: Normal
NCT ID: NCT00196846 Org: User:
Start: 03/31/05 End: 03/31/10 Due: 03/31/11

Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT02789332 Org: User:
Start: 09/30/16 End: 02/29/20 Due: 02/28/21

TBP Study With Capecitabine Plus Minus Trastuzumab

Phase: N/A Priority: Normal
NCT ID: NCT00148876 Org: User:
Start: 09/30/03 End: 01/31/11 Due: 01/31/12

Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO)

Phase: N/A Priority: Normal
NCT ID: NCT00795899 Org: User:
Start: 01/31/02 End: 09/30/08 Due: 09/30/09

Adjuvant Chemotherapy for Elderly Non Frail Patients With an Increased Risk for Relapse of a Primary Carcinoma of the Breast

Phase: N/A Priority: Normal
NCT ID: NCT01204437 Org: User:
Start: 03/31/09 End: 01/31/14 Due: 01/31/15

Postoperative Use of Zoledronic Acid in Breast Cancer Patients After Neoadjuvant Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT00512993 Org: User:
Start: 12/31/04 End: 11/30/13 Due: 11/30/14

Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00793377 Org: User:
Start: - End: 09/30/01 Due: 09/30/02

Long-term Safety and Efficacy of GBG Study Participants

Phase: N/A Priority: Normal
NCT ID: NCT05739591 Org: User:
Start: 10/12/22 End: 05/19/30 Due: 05/19/31